MedPath

Perioperative Hemostasis Management in Liver Transplantation

Recruiting
Conditions
Liver Transplant; Complications
Registration Number
NCT06257407
Lead Sponsor
Société Française d'Anesthésie et de Réanimation
Brief Summary

Liver transplantation (LT) is a surgery with risk of bleeding. Several risk factors have been identified: complex dissection, portal hypertension, history of ascites fluid infections, history of surgical procedures, pre-existing complex hemostatic disorders and those acquired during the procedure. Diffuse bleeding can occur at any time during the 3 phases of surgery: dissection, anhepatic and neohepatic. However, intraoperative bleeding and transfusion requirements remain difficult to predict. Current predictive models are based in particular on preoperative characteristics and do not take into account the course and different phases of the operation.

The need for transfusions has largely decreased over the last 20 years, and currently around 20-25% of patients are transfused (transfusion of at least 1 blood product during LT). However, massive transfusion is necessary in 10% of LT. The European Society of Anaesthesiology (ESA) has issued recommendations on the management of severe bleeding during surgery. However, these recommendations are not specific to LT. Moreover, transfusion strategies vary widely from one center to another. The implementation of protocols within teams dedicated to LT has led to a reduction in bleeding and transfusion, with or without the use of viscoelastic testing.

Intraoperative bleeding and transfusion requirements, as well as postoperative thromboembolic complications, remain difficult to predict. Predictive models of bleeding risk have been developed, but they are based solely on preoperative characteristics and do not take into account the course and various phases of the operation. In addition, new methods such as Bayesian inference or machine learning have been developed, and seem capable of providing different information from that obtained by conventional models.

The overall aim of this prospective multicenter observational study is to investigate the risk factors for bleeding and thrombosis in per- and post-operative LT using different predictive methods, and to describe the management of bleeding and post-operative anticoagulation in metropolitan France.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1200
Inclusion Criteria
  • Patients aged 18 or over
  • Liver transplant patient
Exclusion Criteria
  • Multi-organ transplantation
  • Protected populations: under guardianship or curatorship
  • Patients not affiliated to a social security scheme

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Determine factors that predict the number of red blood cells packed (pRBCs) transfused intraoperatively in LTnumber of pRBCs transfused during surgery

Number of intraoperative pRBCs transfused

Secondary Outcome Measures
NameTimeMethod
Describe haemostatic tests (conventional biological and viscoelastic) carried out intraoperatively on LT. By listing all haemostatic tests performedDuring surgery

Haemostatic tests performed

Describe the post-operative use of anti-aggregants and anticoagulants drugs in LTDuring the first 30 days postoperative LT

Listing of Antiaggregation and thromboprophylaxis used

Measure the possible effect of the various pro- and antihaemostatic treatments on haemorrhagic and thrombotic complications in the first 30 days after LT surgeryDuring the first 30 days postoperative LT

Thrombotic complications and haemorrhagic complications

Explore the links between thombothic events and the results of hemostatic tests (common biological tests and viscoelastic tests)thombotic events observed during the first 30 days postoperative LT

Results of hemostatic tests performed during thrombothic events

Determine haemoglobin mass loss in patients not receiving intraoperative pRBC transfusion of LTDuring surgery

Haemoglobin mass loss

Describe the use of blood products, blood-derived medicinal products and antifibrinolytics administered during each phase of LT and during the first 24 hours postoperatively. By listing all products administered.During surgery

Blood products, blood-derived medicinal products, antifibrinolytics

Determine the predictive factors for intraoperative transfusion of RBCs for LTDuring surgery

(qualitative binary) intraoperative use of packed red blood cells (Y/N)

Determine the predictive factors of the number of RBCs transfused at each phase of LTDuring surgery

(quantitative) number of pRBCs transfused during each of the 3 phases of LT

Determine factors predicting intraoperative bleeding volume in LTDuring surgery

intraoperative bleeding volume

Determine factors predicting transfusion of more than 2 pRBCs intraoperativelyDuring surgery

(qualitative binary) transfusion of more than 2 intraoperative RBCs (Y/N)

Determine the factors predicting the number of RBCs transfused within 24 hours post-LTDuring 24 hours post-LT

(quantitative) number of RBCs transfused in the 24 hours post-LT

Describe postoperative venous thrombotic events (deep vein thrombosis, pulmonary embolism, portal thrombosis) and arterial (graft artery thrombosis) during the first 30 days postoperative LTDuring the first 30 days postoperative LT

Thrombotic complications

To explore the links between bleeding or transfusion and the results of haemostatic tests (conventional biological and viscoelastic) in peri-operative LT. By comparing occurance of bleeding or transfusion and values of haemostatic tests.During operation

Results of haemostatic tests performed after bleeding or transfusion

Trial Locations

Locations (16)

Chru Minjoz

🇫🇷

Besançon, France

CHU Estaing

🇫🇷

Clermont, France

Hôpital Beaujon

🇫🇷

Clichy, France

CHU Grenoble Alpes

🇫🇷

Grenoble, France

CHU Claude Huriez

🇫🇷

Lille, France

Hôpital de la Croix-Rousse

🇫🇷

Lyon, France

CHU La Timone

🇫🇷

Marseille, France

Hôpital St Eloi

🇫🇷

Montpellier, France

Hôpital De L'Archet 2

🇫🇷

Nice, France

CHU Pitié-Salpêtrière

🇫🇷

Paris, France

CHU Haut Levêque

🇫🇷

Pessac, France

CHU Pontchaillou

🇫🇷

Rennes, France

CHU Hautepierre

🇫🇷

Strasbourg, France

CHU Toulouse Rangueil

🇫🇷

Toulouse, France

CHU Tours

🇫🇷

Tours, France

Hôpital Paul Brousse

🇫🇷

Villejuif, France

© Copyright 2025. All Rights Reserved by MedPath